According to filings with the U.S. Securities and Exchange Commission, Avalyn Pharma is raising $189,182,622.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Lyn Baranowski played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Avalyn Pharma
Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow disease progression but are associated with significant side effects, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled medicines to reduce systemic exposure and deliver the medication directly to the disease site. AP01, Avalyn’s lead candidate, is a Phase 2b-ready inhaled formulation of pirfenidone optimized for direct lung delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve efficacy and safety over existing therapy.

To learn more about Avalyn Pharma, visit http://www.avalynpharma.com/

Contact:
Lyn Baranowski, Chief Executive Officer
206-707-0340

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.